ASKA Pharmaceutical Holdings Co.,Ltd.
【Asuka Pharmaceutical】2026 Financial Results｜Net Sales of ¥71.1 Billion, Operating Profit of ¥5.8 Billion, Net Income of ¥5.4 Billion
Asuka Pharmaceutical's consolidated net sales for the Fiscal Year ending March 2026 were ¥71.1 billion, a 10.9% increase YoY. Operating profit was ¥5.8 billion, up 9.4%, and net income was ¥5.4 billion, a 6.3% increase. The company also expanded research and development expenses and overseas operations, strengthening its growth foundation moving forward.
Key Figures
- Net sales: ¥711,127 million (up 10.9% YoY)
- Operating profit: ¥5,834 million (up 9.4% YoY)
- Net income attributable to owners of parent: ¥5,424 million (up 6.3% YoY)
AI要約
Performance Overview
Asuka Pharmaceutical's consolidated results for the fiscal year ending March 2026 totaled net sales of ¥71.1 billion (up 10.9% YoY), operating profit of ¥5.8 billion (up 9.4%), and net income of ¥5.4 billion (up 6.3%). The company achieved increased revenue and profit driven by steady growth in the pharmaceutical business and the addition of new overseas subsidiaries. Research and development expenses also increased, actively promoting clinical trials and partnership activities for new drugs.
Future Outlook and Shareholder Returns
Based on its Mid-term Management Plan 2025, Asuka Pharmaceutical projects continued growth with net sales exceeding ¥73 billion and operating profit over ¥6.0 billion in the fiscal year ending March 2027. The company plans to accelerate overseas expansion and new drug development. It intends to pay an annual dividend of ¥60, implementing a progressive dividend policy. Under the long-term vision 'ASKA VISION 2035,' the company aims to achieve sustainable growth while providing shareholder returns.
Asuka Pharmaceutical Holdings Inc.
Company overview · Stock price · Financial data · All IR
